Answers are grounded in this paper and cite their sources.
Objective To compare the risk of serious psychiatric outcomes among patients with systemic lupus erythematosus initiating belimumab versus oral immunosuppressants. Methods We emulated a target trial using observational data from TriNetX electronic health records database to compare the risks of serious psychiatric events among patients with non-renal SLE initiating belimumab or an oral immunosuppressant (azathioprine, methotrexate, or mycophenolate). Propensity score overlap weighting was used to emulate randomization. The main outcomes were hospitalization for depression and suicide attempt or self-harm. In a per-protocol analysis, we used inverse probability of treatment weighting to adjust for adherence to assigned treatment. A secondary analysis assessed new-onset depression. Results We compared 2434 and 5644 initiators of belimumab and azathioprine, 2163 and 7224 initiators of belimumab and methotrexate, and 2431 and 6350 initiators of belimumab and mycophenolate, respectively. After weighting, baseline covariates were balanced across groups; 95% of patients were female and mean age was 44 years. Belimumab was not associated with an increased risk of hospitalization for depression compared with azathioprine, methotrexate, or mycophenolate. Suicide attempt or self-harm were rare. There was no difference in the risk of new-onset depression among patients without prior mood disorder. Conclusion Among patients with non-renal SLE, belimumab was not associated with increased risk of serious psychiatric events compared with commonly used oral immunosuppressants, supporting its safety in clinical practice.
No takes yet. Share an insight, caveat, or question.
Altynbekova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: